FMP
NASDAQ
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
2.6 USD
-0.4 (-15.38%)
Valuation Date:
Apr 23, 2024 3:58 PM
Share Price on Valuation Date
$2.6
Stock Beta
3.9895277
Shares Outstanding
11514354